Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)
Madrigal Pharmaceuticals, Inc. (MDGL) is a biopharmaceutical company focused on developing therapies for cardiovascular and metabolic diseases. It specializes in using innovative research to create targeted treatments, with a particular emphasis on conditions such as non-alcoholic steatohepatitis (NASH) and related liver diseases.
Company News
Recent insider trading activities reveal interesting signals for CoreWeave and Madrigal Pharmaceuticals. While CoreWeave insiders are selling shares after a significant stock price increase, Madrigal insiders are buying, signaling potential opportunities in AI infrastructure and biotech sectors.
Madrigal Pharmaceuticals reported strong Q2 2025 performance, with GAAP revenue of $212.8 million for its MASH therapy Rezdiffra, exceeding estimates by 31.3%. The company saw rapid patient adoption, with over 23,000 patients on the drug and expanding commercial operations.
Madrigal Pharmaceuticals will release its Q2 2025 financial results on August 5, 2025, and host a live webcast at 8 a.m. Eastern Time to review financial and operating results.
Madrigal Pharmaceuticals reported positive two-year data for its drug Rezdiffra in treating compensated MASH cirrhosis, showing significant reductions in liver stiffness. The company also reported better-than-expected Q4 financial results.
Viking Therapeutics, a biotech firm without any marketed drugs, is set to report its Q2 earnings. Investors will focus on updates related to its pipeline candidates, including VK2809 for NASH and VK2735 for obesity. The company's strong cash balance and robust pipeline development provide growth potential, though it faces competition in the obesi...